Piper Sandler Has Lowered Expectations for Collegium Pharmaceutical (NASDAQ:COLL) Stock Price

by · The Markets Daily

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) had its price objective lowered by research analysts at Piper Sandler from $43.00 to $28.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has a “neutral” rating on the specialty pharmaceutical company’s stock. Piper Sandler‘s price objective points to a potential upside of 11.29% from the company’s previous close.

Several other research analysts have also weighed in on COLL. Zacks Research raised Collegium Pharmaceutical from a “strong sell” rating to a “strong-buy” rating in a research report on Thursday, October 15th. Needham & Company LLC cut their target price on Collegium Pharmaceutical from $46.00 to $44.00 and set a “buy” rating on the stock in a research report on Thursday. Truist Financial assumed coverage on Collegium Pharmaceutical in a research note on Wednesday, September 9th. They set a “buy” rating and a $49.00 target price for the company. Wall Street Zen cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Leerink Partners started coverage on Collegium Pharmaceutical in a report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus target price of $44.88.

Read Our Latest Analysis on COLL

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $25.16 on Friday. Collegium Pharmaceutical has a twelve month low of $21.43 and a twelve month high of $50.79. The firm has a fifty day simple moving average of $23.04 and a 200 day simple moving average of $32.91. The company has a market capitalization of $819.21 million, a PE ratio of 3.39, a P/E/G ratio of 0.74 and a beta of 0.75. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last released its earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.10. The business had revenue of $216.34 million for the quarter, compared to analyst estimates of $216.03 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. Collegium Pharmaceutical’s revenue for the quarter was up 67.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.25 earnings per share. On average, sell-side analysts forecast that Collegium Pharmaceutical will post 6.42 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new position in Collegium Pharmaceutical in the third quarter worth approximately $36,000. PNC Financial Services Group Inc. increased its holdings in shares of Collegium Pharmaceutical by 42.2% during the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 418 shares in the last quarter. Assetmark Inc. increased its holdings in shares of Collegium Pharmaceutical by 9.3% during the first quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 335 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Collegium Pharmaceutical by 15.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,940 shares of the specialty pharmaceutical company’s stock valued at $132,000 after acquiring an additional 778 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in shares of Collegium Pharmaceutical by 20.6% during the first quarter. EverSource Wealth Advisors LLC now owns 5,035 shares of the specialty pharmaceutical company’s stock worth $167,000 after purchasing an additional 861 shares during the period.

More Collegium Pharmaceutical News

Here are the key news stories impacting Collegium Pharmaceutical this week:

  • Positive Sentiment: Q3 adjusted earnings were $1.96 per share, above the cited analyst consensus of $1.86, and revenue of $216.3 million was slightly ahead of estimates. Revenue reached a quarterly record and grew 3% year over year. Collegium Q3 results and guidance
  • Positive Sentiment: Collegium reaffirmed 2026 revenue guidance of $825 million to $855 million, a range with a midpoint above the reported analyst consensus of $832.9 million. The outlook may have helped investor sentiment. Q3 sales and full-year revenue guidance
  • Positive Sentiment: Product trends were encouraging: JORNAY PM revenue increased 24% year over year to $51.9 million, while AZSTARYS generated $26.5 million in its first full quarter under Collegium ownership. The company also announced a $50 million accelerated share repurchase. Quarterly results release
  • Negative Sentiment: Needham lowered its price target to $44 from $46, although it maintained a Buy rating. Q3 earnings per share were also below the year-ago $2.25, despite beating the current-quarter consensus. Needham price target change

Collegium Pharmaceutical Company Profile

(Get Free Report)

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.

Further Reading